134 related articles for article (PubMed ID: 18991711)
1. Imaging of tumor hypoxia to predict treatment sensitivity.
Minn H; Grönroos TJ; Komar G; Eskola O; Lehtiö K; Tuomela J; Seppänen M; Solin O
Curr Pharm Des; 2008; 14(28):2932-42. PubMed ID: 18991711
[TBL] [Abstract][Full Text] [Related]
2. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia imaging agents labeled with positron emitters.
Hoigebazar L; Jeong JM
Recent Results Cancer Res; 2013; 194():285-99. PubMed ID: 22918765
[TBL] [Abstract][Full Text] [Related]
6. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles.
Koch CJ; Evans SM
Adv Exp Med Biol; 2003; 510():285-92. PubMed ID: 12580442
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
9. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
[TBL] [Abstract][Full Text] [Related]
10. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
13. Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Lin LL; Silvoniemi A; Stubbs JB; Rengan R; Suilamo S; Solin O; Divgi C; Eskola O; Sorger JM; Stabin MG; Kachur A; Hahn SM; Grönroos TJ; Forsback S; Evans SM; Koch CJ; Minn H
Cancer Biother Radiopharm; 2012 Sep; 27(7):412-9. PubMed ID: 22897720
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
[TBL] [Abstract][Full Text] [Related]
15. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
[TBL] [Abstract][Full Text] [Related]
16.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
17.
Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
[TBL] [Abstract][Full Text] [Related]
18. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
19. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
Mahy P; De Bast M; Gillart J; Labar D; Grégoire V
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):553-6. PubMed ID: 16523307
[TBL] [Abstract][Full Text] [Related]
20. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
